Dr. Kelly L Larkin, MD
Claim this profileRetina Consultants of Texas
Studies Uveitis
Studies Posterior Uveitis
1 reported clinical trial
1 drug studied
Affiliated Hospitals
More about Kelly L Larkin, MD
Clinical Trial Related2 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 0 Active Clinical TrialsTreatments Kelly L Larkin, MD has experience with
- Fluocinolone Acetonide Intravitreal Implant 0.18 Mg
Breakdown of trials Kelly L Larkin, MD has run
Posterior Uveitis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kelly L Larkin, MD specialize in?
Kelly L Larkin, MD focuses on Uveitis and Posterior Uveitis. In particular, much of their work with Uveitis has involved treating patients, or patients who are undergoing treatment.
Is Kelly L Larkin, MD currently recruiting for clinical trials?
No, Kelly L Larkin, MD is not currently recruiting for any clinical trials. This may change in the future, so check back later.
Are there any treatments that Kelly L Larkin, MD has studied deeply?
Yes, Kelly L Larkin, MD has studied treatments such as Fluocinolone Acetonide Intravitreal Implant 0.18 mg.
What is the best way to schedule an appointment with Kelly L Larkin, MD?
Apply for one of the trials that Kelly L Larkin, MD is conducting.
What is the office address of Kelly L Larkin, MD?
The office of Kelly L Larkin, MD is located at: Retina Consultants of Texas, Bellaire, Texas 77401 United States. This is the address for their practice at the Retina Consultants of Texas.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.